VIPoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| (One intermediate revision by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}} | {{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}} | ||
==Overview== | ==Overview== | ||
Effective [[Measurement|measures]] for the [[secondary prevention]] of VIPoma include [[History and Physical examination|history and physical examination]], [[serum]] [[Vasoactive intestinal peptide|VIP]] levels and [[Indication (medicine)|indicated]] [[Marker|markers]], and multi-phasic [[Computed tomography|CT scan]] or [[MRI]]. | |||
Effective measures for the secondary prevention of [ | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
Effective measures for the secondary prevention of VIPoma include:<ref name="KulkeBenson2012">{{cite journal|last1=Kulke|first1=Matthew H.|last2=Benson|first2=Al B.|last3=Bergsland|first3=Emily|last4=Berlin|first4=Jordan D.|last5=Blaszkowsky|first5=Lawrence S.|last6=Choti|first6=Michael A.|last7=Clark|first7=Orlo H.|last8=Doherty|first8=Gerard M.|last9=Eason|first9=James|last10=Emerson|first10=Lyska|last11=Engstrom|first11=Paul F.|last12=Goldner|first12=Whitney S.|last13=Heslin|first13=Martin J.|last14=Kandeel|first14=Fouad|last15=Kunz|first15=Pamela L.|last16=Kuvshinoff|first16=Boris W.|last17=Moley|first17=Jeffrey F.|last18=Pillarisetty|first18=Venu G.|last19=Saltz|first19=Leonard|last20=Schteingart|first20=David E.|last21=Shah|first21=Manisha H.|last22=Shibata|first22=Stephen|last23=Strosberg|first23=Jonathan R.|last24=Vauthey|first24=Jean-Nicolas|last25=White|first25=Rebekah|last26=Yao|first26=James C.|last27=Freedman-Cass|first27=Deborah A.|last28=Dwyer|first28=Mary A.|title=Neuroendocrine Tumors|journal=Journal of the National Comprehensive Cancer Network|volume=10|issue=6|year=2012|pages=724–764|issn=1540-1405|doi=10.6004/jnccn.2012.0075}}</ref><ref name="KunzReidy-Lagunes2013">{{cite journal|last1=Kunz|first1=Pamela L.|last2=Reidy-Lagunes|first2=Diane|last3=Anthony|first3=Lowell B.|last4=Bertino|first4=Erin M.|last5=Brendtro|first5=Kari|last6=Chan|first6=Jennifer A.|last7=Chen|first7=Herbert|last8=Jensen|first8=Robert T.|last9=Kim|first9=Michelle Kang|last10=Klimstra|first10=David S.|last11=Kulke|first11=Matthew H.|last12=Liu|first12=Eric H.|last13=Metz|first13=David C.|last14=Phan|first14=Alexandria T.|last15=Sippel|first15=Rebecca S.|last16=Strosberg|first16=Jonathan R.|last17=Yao|first17=James C.|title=Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors|journal=Pancreas|volume=42|issue=4|year=2013|pages=557–577|issn=0885-3177|doi=10.1097/MPA.0b013e31828e34a4}}</ref><ref name="BourcierVinik2013">{{cite journal|last1=Bourcier|first1=Matthew E.|last2=Vinik|first2=Aaron I.|title=Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)|journal=Pancreas|volume=42|issue=2|year=2013|pages=348–352|issn=0885-3177|doi=10.1097/MPA.0b013e31825c53fa}}</ref> | Effective [[Measurement|measures]] for the [[secondary prevention]] of VIPoma include:<ref name="KulkeBenson2012">{{cite journal|last1=Kulke|first1=Matthew H.|last2=Benson|first2=Al B.|last3=Bergsland|first3=Emily|last4=Berlin|first4=Jordan D.|last5=Blaszkowsky|first5=Lawrence S.|last6=Choti|first6=Michael A.|last7=Clark|first7=Orlo H.|last8=Doherty|first8=Gerard M.|last9=Eason|first9=James|last10=Emerson|first10=Lyska|last11=Engstrom|first11=Paul F.|last12=Goldner|first12=Whitney S.|last13=Heslin|first13=Martin J.|last14=Kandeel|first14=Fouad|last15=Kunz|first15=Pamela L.|last16=Kuvshinoff|first16=Boris W.|last17=Moley|first17=Jeffrey F.|last18=Pillarisetty|first18=Venu G.|last19=Saltz|first19=Leonard|last20=Schteingart|first20=David E.|last21=Shah|first21=Manisha H.|last22=Shibata|first22=Stephen|last23=Strosberg|first23=Jonathan R.|last24=Vauthey|first24=Jean-Nicolas|last25=White|first25=Rebekah|last26=Yao|first26=James C.|last27=Freedman-Cass|first27=Deborah A.|last28=Dwyer|first28=Mary A.|title=Neuroendocrine Tumors|journal=Journal of the National Comprehensive Cancer Network|volume=10|issue=6|year=2012|pages=724–764|issn=1540-1405|doi=10.6004/jnccn.2012.0075}}</ref><ref name="KunzReidy-Lagunes2013">{{cite journal|last1=Kunz|first1=Pamela L.|last2=Reidy-Lagunes|first2=Diane|last3=Anthony|first3=Lowell B.|last4=Bertino|first4=Erin M.|last5=Brendtro|first5=Kari|last6=Chan|first6=Jennifer A.|last7=Chen|first7=Herbert|last8=Jensen|first8=Robert T.|last9=Kim|first9=Michelle Kang|last10=Klimstra|first10=David S.|last11=Kulke|first11=Matthew H.|last12=Liu|first12=Eric H.|last13=Metz|first13=David C.|last14=Phan|first14=Alexandria T.|last15=Sippel|first15=Rebecca S.|last16=Strosberg|first16=Jonathan R.|last17=Yao|first17=James C.|title=Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors|journal=Pancreas|volume=42|issue=4|year=2013|pages=557–577|issn=0885-3177|doi=10.1097/MPA.0b013e31828e34a4}}</ref><ref name="BourcierVinik2013">{{cite journal|last1=Bourcier|first1=Matthew E.|last2=Vinik|first2=Aaron I.|title=Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)|journal=Pancreas|volume=42|issue=2|year=2013|pages=348–352|issn=0885-3177|doi=10.1097/MPA.0b013e31825c53fa}}</ref> | ||
*History and physical examination | *[[History and Physical examination|History and physical examination]] | ||
*Serum VIP levels and indicated markers | *[[Serum]] [[Vasoactive intestinal peptide|VIP]] levels and [[Indication (medicine)|indicated]] [[Marker|markers]] | ||
*Multi-phasic CT scan or MRI | *Multi-phasic [[Computed tomography|CT scan]] or [[MRI]] | ||
'''Note''': These follow-up should be done every 3 to 12 months up to one year post resection and every 6 to 12 months thereafter. | '''Note''': These follow-up should be done every 3 to 12 months up to one year [[After surgery|post resection]] and every 6 to 12 months thereafter. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 20: | Line 19: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of VIPoma secondary prevention |
|
Risk calculators and risk factors for VIPoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
Effective measures for the secondary prevention of VIPoma include history and physical examination, serum VIP levels and indicated markers, and multi-phasic CT scan or MRI.
Secondary Prevention
Effective measures for the secondary prevention of VIPoma include:[1][2][3]
Note: These follow-up should be done every 3 to 12 months up to one year post resection and every 6 to 12 months thereafter.
References
- ↑ Kulke, Matthew H.; Benson, Al B.; Bergsland, Emily; Berlin, Jordan D.; Blaszkowsky, Lawrence S.; Choti, Michael A.; Clark, Orlo H.; Doherty, Gerard M.; Eason, James; Emerson, Lyska; Engstrom, Paul F.; Goldner, Whitney S.; Heslin, Martin J.; Kandeel, Fouad; Kunz, Pamela L.; Kuvshinoff, Boris W.; Moley, Jeffrey F.; Pillarisetty, Venu G.; Saltz, Leonard; Schteingart, David E.; Shah, Manisha H.; Shibata, Stephen; Strosberg, Jonathan R.; Vauthey, Jean-Nicolas; White, Rebekah; Yao, James C.; Freedman-Cass, Deborah A.; Dwyer, Mary A. (2012). "Neuroendocrine Tumors". Journal of the National Comprehensive Cancer Network. 10 (6): 724–764. doi:10.6004/jnccn.2012.0075. ISSN 1540-1405.
- ↑ Kunz, Pamela L.; Reidy-Lagunes, Diane; Anthony, Lowell B.; Bertino, Erin M.; Brendtro, Kari; Chan, Jennifer A.; Chen, Herbert; Jensen, Robert T.; Kim, Michelle Kang; Klimstra, David S.; Kulke, Matthew H.; Liu, Eric H.; Metz, David C.; Phan, Alexandria T.; Sippel, Rebecca S.; Strosberg, Jonathan R.; Yao, James C. (2013). "Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors". Pancreas. 42 (4): 557–577. doi:10.1097/MPA.0b013e31828e34a4. ISSN 0885-3177.
- ↑ Bourcier, Matthew E.; Vinik, Aaron I. (2013). "Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)". Pancreas. 42 (2): 348–352. doi:10.1097/MPA.0b013e31825c53fa. ISSN 0885-3177.